ReviewArchives of microbiology2025
Beyond traditional therapies: a narrative overview of antimicrobial photodynamic therapy in combating bacterial and viral infections.
Review in Archives of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dual-Photosensitizer Antimicrobial Photodynamic Therapy (DaPDT) and Its Combination with Antibiotics: A New Investigation Modality AgainstPharmaceutics · 2026Article
- Hypericin-Mediated Antimicrobial Photodynamic Therapy in Dentistry: A Systematic Review of Applications Against Oral Biofilms and Infections.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing prevalence of multidrug-resistant bacteria and emerging viruses urgently requires new antimicrobial approaches. Photodynamic therapy (PDT) combining light, photosensitizers, and molecular oxygen generates reactive oxygen species (ROS) that disrupt microbial cells, including in biofilms. In this review, we present recent clinical and preclinical evidence for PDT's effectiveness against both Gram-positive and Gram-negative bacteria, oral/dental pathogens, and viral structures. We highlight applications such as periodontal therapy, root canal disinfection, denture stomatitis, and skin/surface fungal infections. Findings show that PDT produces large log reductions in bacterial counts, dismantles biofilm architecture, and yields improvements in clinical measures (e.g., reduced probing depth and bleeding). Although safety appears favorable, the main limitations are inconsistent photosensitizer types, variable light doses and treatment durations, and a shortage of large-scale clinical trials. PDT holds strong potential not only as an adjunct but possibly as a primary therapy against infections by multidrug-resistant pathogens. Future work should focus on standardizing protocols, optimizing delivery systems (e.g., via nanotechnology or nano-drug delivery systems), and conducting larger, rigorous clinical trials to establish PDT's routine use in infectious disease management.
Indexed as
Identifiers
41222590What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.